( RESEARCH TRIANGLE PARK N.C. & GENE...)New Information on the Potential of Plasmin Shared at ISTH Congress,Health

RESEARCH TRIANGLE PARK, N.C. & GENEVA--(BUSINESS WIRE)--Jul 11, 2007 - New information representing the continuing research and development program for Plasmin (Human), TAL-05-00018, was presented by Talecris Biotherapeutics, Inc. (http://www.talecris.com) this week at the XXIst International Society for Thrombosis and Haemostasis (ISTH) Congress in Geneva, Switzerland. The information included new data and updates on continuing research and development of Plasmin as a potential new thrombolytic to treat acute clotting disorders, such as peripheral arterial occlusion, deep vein thrombosis, and ischemic stroke.

Plasmin, which is derived from human plasma, is a unique locally-acting, fibrin-specific thrombolytic that can be infused directly into a clot via a catheter using minimally invasive techniques. "Plasmin, because of its local action and strong fibrin binding properties, has the potential to provide improvements when treating patients with acute clotting disorders," said Victor Marder, M.D., Chairman, David Geffen School of Medicine at University of California, Los Angeles (UCLA). "We look forward to plasmin's continued development as well as the continuing efforts to further characterize its possible advantages as a locally-acting thrombolytic."

Plasmin Posters Presented at ISTH 2007

1. PRIORITY Trial - Plasmin Revascularization of Acute Lower Extremity Native Artery or Bypass Graft Occlusion - Study Design (Abstract # P-S-691):

-- The Phase I/II PRIORITY trial has now enrolled three patients and is on target.

-- Data from the study will be used to select appropriate dosing to move into Phase III for treating patients with acute arterial peripheral occlusion (aPAO).

2. Safety results of the first clinical trial in humans of Plasmin to evaluate safety and establish effective dosing for Hemodialysis Graft Occlusion (Abstract #P-S-385):

-- Data from this study de
'"/>

Page: 1 2 3 4
Related medicine technology :

1. International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinsons Disease
2. FDA Announces Audio Broadcasts on Emerging Drug Safety Information
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
6. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
7. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
8. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
9. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
10. New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes
11. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease